Take‑profit recommendation to trim approximately one third of existing positions in both Paladin Energy (PDN) and iShares Global Healthcare ETF (IXJ, ASX), realising recent gains while maintaining meaningful exposure to the uranium and global healthcare themes.
Taking profits in our Gold miners and Uranium Stocks to buy U.S. healthcare ETFs could be a good strategic move as a resolution of the U.S. government shutdown (now into its 16th day, double the average shutdown) would restore market confidence and strengthens the dollar.
Our investment thesis is based on a powerful macro catalyst: a structural, multi-year increase in uranium
demand driven by the insatiable power requirements of AI datacenters. Recent US policy shifts, including a
$2.7 billion domestic uranium procurement plan and a pivotal US-UK nuclear pact, are accelerating this trend,
creating a highly favourable outlook for the entire uranium sector.
The Reserve Bank of Australia (RBA) has taken a significant step by lowering its cash rate from 4.35% to 4.10%—its first cut since 2020. This decision marks an important pivot in monetary policy, aimed at supporting economic recovery while keeping inflation in check.
Following the earnings release, the stock experienced a sharp 7% sell-off at market open. This pronounced negative reaction indicates that investors are increasingly wary of the sustainability of the reported earnings growth amid evident headwinds.
Challenger exceeded EPS expectations and maintained strong capital and cost control, but asset and liability experience losses, weaker annuity sales, and accounting distortions impacted statutory profits. While structural improvements in capital efficiency and expense management are evident, sales momentum in annuities remains a key challenge going into H2 FY25.
Challenger exceeded EPS expectations and maintained strong capital and cost control, but asset and liability experience losses, weaker annuity sales, and accounting distortions impacted statutory profits. While structural improvements in capital efficiency and expense management are evident, sales momentum in annuities remains a key challenge going into H2 FY25.
Audinate Group Limited reported 1H25 earnings that exceeded market expectations, particularly in terms of EPS (-$0.02 vs. -$0.12 expected). However, the company remains in a transitional phase, dealing with ongoing inventory overhang from OEM customers while seeing promising growth in software revenues and product mix shifts.
Earnings update for Macquarie group MQG:ASX
Kai Chen and Mark Gardner talk about the next phase of AI investment
Business update for Telix pharma TLX:ASX
BUY 5% Intl Quality ETF (QUAL)
BUY 5% CSL (CSL)
ADD 2.5% Johns Lyng Grp (JLG)
Switch URNM ETF to Paladin